Clinical trial
Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed…
NCT00033241 · OSI Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00033241 |
|---|---|
| Title | Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors |
| Official title | A Phase Ib Multicenter Trial To Determine The Safety, Tolerance And Preliminary Antineoplastic Activity Of Gemcitabine Administered In Combination With Escalating Oral Doses Of OSI-774 To Patient Cohorts With Recently Diagnosed, Gemcitabine-Naive, Advanced Pancreatic Carcinoma Or Other Potentially… |
| Lead sponsor | OSI Pharmaceuticals, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | erlotinib hydrochloride, gemcitabine hydrochloride |
| Start date | Jul 23, 2001 |
| Primary completion | Apr 22, 2004 |
| Completion | Apr 22, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 10, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: